Skip to main content

Advertisement

SpringerLink
Log in

Time for a new approach to drug development for rare systemic autoinflammatory diseases

  • Comment
  • Published:

From Nature Reviews Rheumatology

View current issue Sign up to alerts

Despite the transformative potential of treatments for systemic autoinflammatory diseases, these conditions remain underfunded and understudied. Urgent, coordinated action among stakeholders is needed to overcome regulatory and research barriers, as is innovation and advocacy for the development of effective therapies for these rare diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Downing, N. S., Aminawung, J. A., Shah, N. D., Krumholz, H. M. & Ross, J. S. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. J. Am. Med. Assoc. 311, 368 (2014).

    Article  CAS  Google Scholar 

  2. European Medicines Agency. Clinical trials on human medicines. https://www.ema.europa.eu/en/human-regulatory/research-development/clinical-trials-human-medicines (accessed 3 August 2023).

  3. Piskin, D. et al. Developing guidelines for ultrarare rheumatic disorders: a bumpy ride. Ann. Rheum. Dis. 81, 1203–1205 (2022).

    Article  Google Scholar 

  4. Di Donato, G., d’Angelo, D. M., Breda, L. & Chiarelli, F. Monogenic autoinflammatory diseases: state of the art and future perspectives. Int. J. Mol. Sci. 22, 6360 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Romano, M. et al. The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Ann. Rheum. Dis. 81, 907–921 (2022).

    Article  CAS  PubMed  Google Scholar 

  6. United States Congress. Orphan Drug Act of 1983. 96 Stat. 2049 (1983).

  7. Brown, D. G. A Drug discovery perspective on FDA expedited development and incentive programs. J. Med. Chem. https://doi.org/acs.jmedchem.3c02165 (2024).

  8. Yates, N. & Hinkel, J. The economics of moonshots: Value in rare disease drug development. Clin. Transl. Sci. 15, 809–812 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  9. U.S. Food and Drug Administration. KINERET® (Anakinra) Injection, for Subcutaneous Use. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103950s5136lbl.pdf (2020).

  10. Arnold, D. D., Yalamanoglu, A. & Boyman, O. Systematic review of safety and efficacy of IL-1-targeted biologics in treating immune-mediated disorders. Front. Immunol. 13, 888392 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

E.D. and R.G.M. are co-founders of TARN, N.M.Z. is a coordinator of TARN, and M.R. is a member of its steering committee. The authors would like to acknowledge other core steering committee members of TARN: S. Canna, F. Dedeoglu and K. Durrant. We also extend our gratitude to F. Garcia-Bournissen for invaluable contributions to the conceptualization of this Comment, which were pivotal in refining the arguments and perspectives explored.

Author information

Authors and Affiliations

  1. Department of Pediatrics, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada

    Natalie M. Zitoun, Erkan Demirkaya & Micol Romano

  2. Canadian Behcet’s and Autoinflammatory Diseases Center, University of Western Ontario, London, Ontario, Canada

    Erkan Demirkaya & Micol Romano

  3. Translational Autoinflammatory Diseases Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA

    Raphaela Goldbach-Mansky

Authors
  1. Natalie M. Zitoun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Erkan Demirkaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raphaela Goldbach-Mansky
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Micol Romano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Micol Romano.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zitoun, N.M., Demirkaya, E., Goldbach-Mansky, R. et al. Time for a new approach to drug development for rare systemic autoinflammatory diseases. Nat Rev Rheumatol (2024). https://doi.org/10.1038/s41584-024-01108-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41584-024-01108-6

  • Springer Nature Limited

Search

Navigation